OptiBiotix Health plc (LON:OPTI) said its cholesterol product had been generally recognised as safe (GRAS) by an independent expert panel in the US. OptiBiotix Chief Executive Stephen O’Hara tells Proactive London why the company, which is developing products to tackle obesity, cardiovascular disease and diabetes, said sign-off for its Lactobacillus plantarum LPLDL probiotic strain represented a significant milestone. It's simply because GRAS designation is required for food additives in the States. In the case of probiotics, it is strain-specific. Assessment involves submitting an extensive technical dossier for evaluation and the GRAS panel that reviewed LPLDL concluded the bacteria strain was safe for use in food and beverages at a concentration of up to 10bn colony forming units per serving. This is more than double the dose found to significantly reduce cholesterol and blood pressure in a human trial conducted by Reading University. O’Hara added: “This is a significant achievement and a major commercial milestone as it expands the potential applications of LPLDL from use as a supplement to use as a functional ingredient in a wide range of food, dairy, beverage, and high-value medical food applications, across the USA."
OptiBiotix cholesterol product 'generally recognised as safe' by US independent expert panel
Quick facts: OptiBiotix Health PLC
Price: 51 GBX
Market Cap: £44.85 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of OptiBiotix Health PLC named herein, including the promotion by the Company of OptiBiotix Health PLC in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE